ESSA Provides an Update on its Clinical Collaboration with Janssen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
ESSA Pharma Inc. (EPIX) Declines 27% After Janssen Suspends Enrollment in Phase 1 Study of EPI-7386
October 31, 2022 7:10 AM EDTESSA Pharma Inc. (NASDAQ: EPIX) Declines 27% After Janssen Suspends Enrollment in Phase 1 Study of EPI-7386
... More